David DeNardo

Medicine & Life Sciences

1. Neoplasms 100%
2. Pancreatic Neoplasms 89%
3. Breast Neoplasms 64%
4. Macrophages 63%
5. Adenocarcinoma 60%
6. T-Lymphocytes 50%
7. Immunotherapy 47%
8. Immunity 44%
9. Myeloid Cells 29%
10. Myeloid-Derived Suppressor Cells 28%
11. Tumor Microenvironment 28%
12. Breast 28%
13. Neoplasm Metastasis 27%
14. Carcinogenesis 27%
15. Cancer-Associated Fibroblasts 24%
16. Focal Adhesion Protein-Tyrosine Kinases 23%
17. Immunosuppressive Agents 22%
18. Monocytes 18%
19. Growth 16%
20. Bexarotene 16%
21. Radioimmunotherapy 15%
22. Therapeutics 14%
23. Leukocytes 13%
24. yttrium(III)-1,4,7,10-tetraazacyclotetradecane-N,N',N'',N'''-tetraacetic acid 12%
25. copper(II)-1,4,8,11-tetraazacyclotetradecane-N,N',N'',N'''-tetraacetic acid 12%
26. defactinib 11%
27. Radiotherapy 11%
28. Paclitaxel 11%
29. SV119 11%
30. Retinoids 11%
31. Neoplastic Stem Cells 11%
32. PF-04136309 11%
33. Optical Imaging 11%
34. Granulocyte-Macrophage Colony-Stimulating Factor 11%
35. Hematopoiesis 11%
36. ChL6 monoclonal antibody 11%
37. Inflammation 10%
38. Immunosuppression 10%
39. Transcription Factors 10%
40. Dendritic Cells 10%
41. Stromal Cells 10%
42. Innate Immunity 10%
43. Chemokines 9%
44. Estrogen Receptors 9%
45. Estrogens 9%
46. erastin 9%
47. Radiation 9%
48. 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine 9%
49. Nanoparticles 9%
50. Discoidin Domain Receptor 2 8%